Evidence map›Paper›PMID 41239168›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno-venous hemofiltration.

Sai Tian, Yong Chen, Mingjie Qiu, Wenqi Wu, Liuqing Dou, Jiajie Wang, Li Xu, Zhitao Zhou, Meilin Wu, Jiayang Li and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sai Tian *Research Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Yong Chen *Institute of Laboratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People's Republic Of China.
Mingjie QiuResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Wenqi WuSchool of Medicine, Nanjing University, Nanjing, People's Republic of China.
Liuqing DouResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Jiajie WangSchool of Medicine, Southeast University, Nanjing, People's Republic of China.
Li XuResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Zhitao ZhouResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Meilin WuResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Jiayang LiSchool of Medicine, Nanjing University, Nanjing, People's Republic of China. jiayanglinj@163.com.
Xiuwen WuResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China. wuxiuwen@nju.edu.cn.
Jianan RenResearch Institute of General Surgery, Jinling Hospital, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China. jiananr@nju.edu.cn.

Funding

the Key Research and Development Program of Jiangsu Province BE2022823the Navigation Project of Clinical Research 22LCYY-LH4
6 · The paper itself

Abstract

purposeTo investigate the pharmacokinetics (PK) of ceftazidime/avibactam and optimize dosing regimens in patients with severe intra-abdominal infection (sIAI) receiving continuous veno-venous hemofiltration (CVVH).

methodsSeven patients with sIAI treated with ceftazidime/avibactam and CVVH were enrolled. Blood samples were collected at pre-dose and post-dose (2, 3, 4, 6, and 8 h) during hemodynamic stability. Plasma concentrations were measured, and PK parameters were calculated. Monte Carlo simulations (MCSs) were used to assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) for different dosing regimens.

resultsCVVH increased the clearance (CL) significantly (ceftazidime: 2.46 ± 0.29 vs. 0.9 ± 0.11 L/h; avibactam: 2.89 ± 0.41 vs. 1.09 ± 0.08 L/h, p < 0.001). For the target of 100%fT ≥ MIC (ceftazidime) + 100%fT ≥ C

conclusionCVVH enhanced the CL significantly. Dosing should be "individualized" based on the MIC and patient-specific factors.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeHemofiltrationIntraabdominal InfectionsAdultAgedAged, 80 and overDrug CombinationsFemaleHumansMaleMiddle AgedMonte Carlo MethodAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug CombinationsCeftazidime/avibactamContinuous veno–venous hemofiltrationMonte carlo simulationPharmacokinetic/pharmacodynamicSevere intra-abdominal infection

Identifiers

PMID41239168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.